Tag Archives: Investors

RESI@TMCx Panel Announcement: Incubators, Accelerators & New Models

17 Mar

By Lucy Parkinson, Director of Research, LSN

With the explosion of activity in early stage life sciences in the last few years, many new programs have been formed to support the youngest new biotech, medtech and healthcare IT companies in developing their products and making first steps toward commercialization.

This RESI panel will highlight five programs that provide vital resources at the earliest stage, including support, work space, mentoring, business education, and investment. The panelists will talk about how they select companies, how they help entrepreneurs turn scientific ideas into commercial success stories, and what makes each of their programs unique.

Moderated by Atul Varadhachary, Managing Partner, Fannin Innovation Studio, this session will feature:

Tags: , , , , , ,

RESI@TMCx Panel Announcement: Early Stage Therapeutic Investors

10 Mar

By Lucy Parkinson, Director of Research, LSN

Early stage therapeutics companies have a long road ahead to reach the marketplace, and will require significant investment along their way. The level of risk involved at this stage deters some investors, and much has been written about the pull-back of many venture capital firms from this phase of investment. At RESI, a panel of 5 investors who are highly experienced in investing in early stage therapeutic development will discuss how they pick winning scientfic teams and support their portfolio companies through the challenges of the development process.

Moderated by Lisa Rhoads, Managing Director, Easton Capital, the panel will feature:

This panel will give fundraising entrepreneurs a firsthand look at the strategies used by early stage therapeutic investors to assess companies at the earliest, riskiest stage of development, and will help the audience to position their companies as an attractive investment opportunity.

By registering for RESI@TMCx, you’ll be able to listen to the early stage therapeutic panel live in person, and also experience numerous opportunities to expand your network in the life sciences and to learn more about the fundraising process.

RESI-Houston-2016_600

Tags: , , , , , , , ,

RESI@TMCx Panel Announcement: Venture Philanthropy Investors

10 Mar

By Christine A. Wu, Research Analyst, LSN

chrsitine

Venture philanthropy organizations provide more than just financing. Often times, these investors can provide a network of experts, patients, and resources in their niche space. Here in Next Phase, LSN has previously covered trends in venture philanthropy investment and advice in how to approach venture philanthropy investors.

LSN is pleased to announce a panel of five investors in the venture philanthropy space for RESI@TMCx on April 11th. Moderated by Jit Patel, VP of Research and Business Development of Juvenile Diabetes Research Foundation (JDRF), the panel will be joined by:

Panelists will address their specific investment criteria and unique missions; their investment decision-making process; important trends in the space; and the best approach to reach and heighten their interest.

Interested in this panel? It’s not too late to register for RESI@TMCx Houston and see this panel live. View the full RESI@TMCx agenda here. You can also view a video recap of our RESI San Francisco Venture Philanthropy session.

RESI-Houston-2016_600

Tags: , , , , , ,

RESI@TMCx Take 2: LSN, JLABS and TMCx Team-up Again for Early Stage Investor Event

21 Jan

By Michael Quigley, VP of Market Research, LSN

mike-2

On April 11th, Life Science Nation will be bringing together hundreds of senior level executives from investment firms, corporate strategics, and emerging biotech, medtech and digital health companies to the TMCx accelerator space at the Texas Medical Center in Houston. The recent RESI Conference in San Francisco had nearly 800 registrants and a full partnering floor. The event drew so much interest that registration was shut down a week prior to the event – and we received many regretful notes from those who wished they’d signed up sooner!

In addition to the firepower that LSN brings to the table, TMCx will be showcasing their second class of digital health and medical device technologies which will be announced later this month, and JLABS will be bringing senior executives from Johnson & Johnson and a number of entrepreneurs from the JLABS incubators.

RESI@TMCx will be a venue for entrepreneurs to meet with all 10 categories of investors LSN tracks including Family offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more. The RESI Partnering Forum will allow fundraising executives to identify and book up to 16 meetings with those diverse life science investors who fit their company’s technology sector and stage of development. Through an expansive series of investor panels, RESI @ TMCx will present current topics covering investment mandates and procedures for identifying and qualifying candidates. Additionally, RESI’s workshops will provide more in-depth advice on every aspect of the fundraising process.

 

RESI-Houston-2016_600

eb

Tags: , , , , , , , ,

Redefining Early Stage Investments (RESI) Conference: Healthcare IT Investors Panel

17 Dec

By Shaoyu Chang, MD, MPH,  Senior Research Manager, LSN

Shaoyu 10*10

At the intersection between life science and computer science, healthcare IT continues to attract strong interests from both camps. VC funds, big pharmas, and tech corporates are all actively seeking the next big thing in HCIT that would transform healthcare fundamentally.

Some of the biggest players in HCIT investment will speak at RESI San Francisco to share their expertise and advice with entrepreneurs. Moderated by Anne DeGheest, Founder of HealthTech Capital, the panel will feature:

This panel will provide fundraising entrepreneurs with an inside peak into the strategy of these HCIT investors – How do you make your company stand out in this crowded marketplace? What do investors see as the most high-potential fields of innovation in healthcare IT? How do you demonstrate to an investor that your product has the potential to succeed?

If you’re interested in listening to this panel live at RESI, you can register for RESI San Francisco now. RESI provides a great opportunity to expand your network in the life sciences and to get a better understanding of fundraising process, and January 12th will be our largest gathering yet.

RESI-San-Francisco-2016

Tags: , , , , , ,

Redefining Early Stage Investments (RESI) Conference: Orphan & Rare Disease Investors Panel

10 Dec

By Christine A. Wu, Research Analyst, LSN

chrsitine

The orphan and rare disease space has gained significant traction among life science investors. Despite the smaller market populations and limited clinical trial participants in rare diseases, technology in this space has remained attractive to investors due to its expedited FDA process and its lack of current treatment options for such uncommon conditions. Overall, while there are many challenges, there remains a lot of hope to drastically impact patient populations, scientific advancement, and market potential.

RESI San Francisco will bring together well-established investors in the rare and orphan disease space on January 12th. Moderated by Mark Day, Executive Director and Head of External Research & Scouting of Alexion Pharmaceuticals, panelists will include:

Panelists will discuss the attractiveness of orphan and rare disease technologies in comparison to non-orphan opportunities; what the rare disease spaces offers to investors; the best way to position an orphan opportunity to a potential investor; the evaluation process in assessing products in the space; as well as common trends, challenges, and excitement in the scientific advancement of the field.

To all the hopefuls in the orphan and rare disease space, this panel is for you. Register for RESI San Francisco now to hear this panel live – partnering has already begun and this event will be LSN’s biggest RESI yet.

RESI-San-Francisco-2016

Tags: , , , ,

RESI Panel Announcement: Diagnostic Investors

3 Dec

By Nicholas Civitarese, Research Analyst, LSN

nick-wp

The amount of capital being invested in medical technology and diagnostics is at its highest point since 2008. However, companies in the diagnostics space face some unique challenges in the fundraising landscape.

To inform your fundraising campaign’s direction, Life Science Nation is pleased to announce a panel of six investors with expertise in the diagnostics space for RESI San Francisco on January 12th. Moderated by Akhil Saklecha, Partner at Artiman Ventures, the panel will feature:

This panel will provide fundraising entrepreneurs with an inside peak into the strategy of these diagnostic investors – including best practices for building relationships with diagnostic investors as well as advice on making sure your diagnostic company is positioned as a strong investment opportunity.

If you’re interested in listening to this panel live at RESI, you can register for RESI San Francisco now. RESI provides a great opportunity to expand your network in the life sciences and to get a better understanding of fundraising process, and January 12th will be our largest gathering yet.

RESI-San-Francisco-2016

Tags: , , , , , , ,

← Older Entries
Newer Entries →